- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03538054
Dextromethorphan in Fibromyalgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fibromyalgia (FM) is a chronic, widespread pain syndrome. Individuals with FM frequently report body pain, fatigue, sleep issues, cognitive impairment, headaches, and other symptoms. The disease affects approximately 5% of women in the United States. Many of those patients suffer with decreased quality of life and loss of employment.
The precise pathological mechanism of FM is not yet understood, and there is no targeted treatment for the condition. One hypothesis of FM with prior scientific support is that pain is caused by abnormal inflammation of the brain. When microglia cells in the brain adopt an inflammatory state, they release chemicals that can cause neurons to increase the transmission of pain signals.
DXM has been used in previous research and demonstrated to suppress pain symptoms. When given at higher dosages (above 200mg), the medication acts as a dissociative agent. This dosage can reduce pain, but produces side-effects that can limit daily functioning. At lower dosages, however, DXM may reduce inflammatory aspects of chronic pain while not causing dissociative side effects.
In animal models, central inflammation can be reduced with intraperitoneal dosages of DXM of 0.1mg/kg. In an average U.S. woman, this dosage would translate to approximately 8mg. Because an oral versus intraperitoneal dosing route will be used, the dose will be raised to 10mg, administered twice a day (once in the morning and once at night). The investigator will examine the impact of 20mg total daily DXM on self-reported FM pain.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama of Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe chronic fatigue ≥6 consecutive months not due to ongoing exertion or other medical condition associated with fatigue;
- Daily self-reported pain of at least 4 out of 10;
3. Meets American College of Rheumatology 2016 case definition criteria for FM;
4. Able to attend UAB for all scheduled appointments;
5. Can complete daily self-reports of pain and other symptoms for duration of project.
Exclusion Criteria:
- Blood draw contraindicated or otherwise not able to be performed;
- High-sensitivity C-reactive protein (HS-CRP) ≥ 10 mg/L;
- Erythrocyte sedimentation rate (ESR) >60 mm/hr;
- Positive rheumatoid factor;
- Positive anti-nuclear antibody (ANA);
- Abnormal thyroid stimulating hormone or free thyroxine;
- Diagnosed rheumatologic or auto-immune condition;
- Blood or clotting disorder;
- Use of blood thinning medication;
- Current use of MAOI
- Daily consumption of grapefruit juice
- Oral temperature >100˚F at baseline;
- Febrile illness or use of antibiotics in the 4 weeks before study commencement;
- Planned surgery or procedures during the study period, or operated on in the 4 weeks before study commencement;
- Pregnant or planning on becoming pregnant within 6 months, or currently breastfeeding
- Regular use of any anti-inflammatory medication (such as aspirin, ibuprofen, naproxen);
- Baseline HADS (Hospital Anxiety and Depression Scale) depression subscale score of ≥16;
- Current litigation or worker's compensation claim;
- Current participation in another treatment trial;
- Planned vaccination during the study period, or vaccinated in the 4 weeks before study commencement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dextromethorphan
Participant will take one dextromethorphan 10mg capsule in the morning and at night.
|
(1)10 mg, by mouth, twice daily every 12 hours.
|
Placebo Comparator: Placebo
Participants will take one placebo capsule in the morning and at night.
|
1 capsule, by mouth, twice daily every 12 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Self-reported Pain Severity
Time Frame: Daily over 4 weeks
|
Daily self-reported widespread pain severity, rated on a 0 - 100 scale (0 = no pain and 100 = worst pain possible).
Participants' daily scores from the last 4 weeks of each condition (placebo and dextromethorphan) were summed and then averaged across the 4-week time period.
|
Daily over 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Self-reported Physical Activity
Time Frame: Daily over 4 weeks
|
Self-reported daily activity, rated from 0 - 100 where 0 is less daily activity and 100 is the most amount of daily activity.
Participants' daily scores from the last 4 weeks of each condition (placebo and dextromethorphan) were summed and then averaged across the 4-week time period.
|
Daily over 4 weeks
|
Patient Global Impression of Change
Time Frame: 20 weeks
|
Patient global impression of change (PGIC) measured on a seven point likert scale (1 = "no change" to 7 = "a great deal better").
PGIC's were not administered to participants.
The PGIC was inadvertently left out of the lab visit packet.
Since the PGIC was not administered, data was not collected for both arms/groups.
|
20 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jarred W Younger, PhD, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Fibromyalgia
- Myofascial Pain Syndromes
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Respiratory System Agents
- Antitussive Agents
- Dextromethorphan
Other Study ID Numbers
- F161018005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on Dextromethorphan
-
Boehringer IngelheimCompleted
-
PfizerCompletedHealthy VolunteersBelgium
-
National Institute of Neurological Disorders and...CompletedParkinson's Disease | Neurodegenerative DiseaseUnited States
-
National Institute of Dental and Craniofacial Research...CompletedDiabetic Neuropathies | Neuralgia | Herpes ZosterUnited States
-
Medical University of South CarolinaCompletedMajor Depressive Disorder
-
Hugo W. Moser Research Institute at Kennedy Krieger...The Johns Hopkins Institute for Clinical and Translational Research (ICTR)CompletedRett SyndromeUnited States
-
National Institute on Drug Abuse (NIDA)Unknown
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Fatigue | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer Disease | Huntington DiseaseUnited States